New England Has $7.6 Billion Worth of Reasons to Embrace the Pharmaceutical-Biotech Industry

New England Has $7.6 Billion Worth of Reasons to Embrace the Pharmaceutical-Biotech Industry

New England Has $7.6 Billion Worth of Reasons to Embrace the Pharmaceutical-Biotech Industry


Attachment: lifescience

SUGAR LAND--July 20, 2016--Reported by Annette Kreuger, Industrial Info Resources (Sugar Land, Texas)--New England has long been a favorite of the Pharmaceutical-Biotech Industry, hosting an impressive roster of the top biotech and pharmaceutical companies, along with nascent but promising start-ups. The region's attractions include formidable intellectual capacity and strong governmental support. A recent analysis of Industrial Info's Pharmaceutical-Biotech Industry database revealed $7.6 billion in active reported projects in New England. Within this article: Details of Pfizer's (NYSE:PFE) pharma-bio project in Andover, Massachusetts.

Subscribe Now!(All Fields Required)

Standard Membership - Free